SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001737287-22-000035
Filing Date
2022-05-04
Accepted
2022-05-04 16:19:13
Documents
61
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20220331.htm   iXBRL 10-Q 1389197
2 EX-31.1 allo-20220331xex311.htm EX-31.1 9885
3 EX-31.2 allo-20220331xex312.htm EX-31.2 9855
4 EX-32.1 allo-20220331xex321.htm EX-32.1 7110
  Complete submission text file 0001737287-22-000035.txt   6192989

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20220331.xsd EX-101.SCH 43070
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20220331_cal.xml EX-101.CAL 51543
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20220331_def.xml EX-101.DEF 224839
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20220331_lab.xml EX-101.LAB 567603
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20220331_pre.xml EX-101.PRE 354541
55 EXTRACTED XBRL INSTANCE DOCUMENT allo-20220331_htm.xml XML 947292
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 22891773
SIC: 2836 Biological Products, (No Diagnostic Substances)